Emergence of Candida albicans fungemia during voriconazole therapy

Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies

“…It was notably more potent against C. krusei and C. glabrata than fluconazole and showed similar MICs to itraconazole for most susceptible isolates. This is consistent with published data for various isolate collections [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15] and clinical cases [7,[18][19][20][21]23].…”

“…There is an extensive literature detailing the in vitro susceptibility of yeasts to voriconazole [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15]. However, there are fewer published studies examining the susceptibility of yeast isolates from voriconazole-treated patients [7,[16][17][18][19][20][21]. This study provides data on yeasts isolated from patients included in the voriconazole clinical studies database.…”